Biomarkers of cognitive decline in Parkinson's disease.
作者： Chin-Hsien Lin , Ruey-Meei Wu
DOI: 10.1016/J.PARKRELDIS.2015.02.010
关键词:
摘要: Cognitive impairment is a frequent and devastating non-motor symptom of Parkinson's disease (PD). Impaired cognition has major impact on either quality life or mortality in patients with PD. Notably, the rate cognitive decline pattern early deficits PD are highly variable between individuals. Given that underlying mechanisms dementia associated remain unclear, there currently no mechanism-based treatment available. Identification biological markers, including neuroimaging, biofluids common genetic variants, account for heterogeneity related could provide important insights into pathological processes underlie These combined biomarker approaches will enable diagnosis indicators progression patients. This review summarizes recent advances development biomarkers impairments
elsevier.com
sci-hub.se 参考文章(182)
Susan E. Folstein, Marshal F. Folstein, Paul R. McHugh, F. Folstein, A PRACTICAL METHOD FOR GRADING THE COGNITIVE STATE OF PATIENTS FOR THE CLINICIAN ,(2002)
Brian J. Mainland, Kenneth I. Shulman, Clock Drawing Test Cognitive Screening Instruments. pp. 79- 109 ,(2013) , 10.1007/978-1-4471-2452-8_5
K. A. Jellinger, Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study Journal of Neural Transmission. Supplementa. pp. 91- 104 ,(2007) , 10.1007/978-3-211-73574-9_12
Roger Lane, Yunsheng He, Christopher Morris, James B. Leverenz, Murat Emre, Clive Ballard, BuChE-K and APOE ϵ4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline† Movement Disorders. ,vol. 24, pp. 392- 400 ,(2009) , 10.1002/MDS.22357
Mona K. Beyer, Guido Alves, Kristy S. Hwang, Sona Babakchanian, Kolbjorn S. Bronnick, Yi-Yu Chou, Turi O. Dalaker, Martin W. Kurz, Jan P. Larsen, Johanne H. Somme, Paul M. Thompson, Ole-Bjørn Tysnes, Liana G. Apostolova, Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease. Movement Disorders. ,vol. 28, pp. 302- 310 ,(2013) , 10.1002/MDS.25282
Dag Aarsland, Mona K Beyer, Martin W Kurz, Dementia in Parkinson's disease. Current Opinion in Neurology. ,vol. 21, pp. 676- 682 ,(2008) , 10.1097/WCO.0B013E3283168DF0
Harold Goodglass, Edith Kaplan, The assessment of aphasia and related disorders ,(1972)
G. G. Fillenbaum, A. Heyman, Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neurology. ,vol. 44, pp. 228- 228 ,(2002) , 10.1002/0470846410.CH42(III)
Wataru Sako, Nagahisa Murakami, Yuishin Izumi, Ryuji Kaji, Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Movement Disorders. ,vol. 29, pp. 1599- 1605 ,(2014) , 10.1002/MDS.26036
Jennifer G. Goldman, Caroline Williams-Gray, Roger A. Barker, John E. Duda, James E. Galvin, The spectrum of cognitive impairment in Lewy body diseases Movement Disorders. ,vol. 29, pp. 608- 621 ,(2014) , 10.1002/MDS.25866